Higher product sales help Amgen beat analyst expectations for first quarter

You are here: Home > Central Coast Health Watch > Current Article

Higher product sales help Amgen beat analyst expectations for first quarter

By Staff Report / Tuesday, April 24th, 2018 / Comments Off on Higher product sales help Amgen beat analyst expectations for first quarter

Amgen's first quarter revenues and earnings per share beat analyst expectations, reaching $5.6 billion and $3.25 respectively on higher product sales, the company reported April 24. In particular, the Thousand Oaks biotech giant’s cholesterol drug Repatha saw a 151 percent increase in sales after receiving U.S. Food and Drug Administration approval in December to be…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.